RT @sgvet1209: 犬のリンパ腫の新規治療薬Verdinexor(KPT-335)のPhase Ⅱ試験 ・XPO1を選択的に阻害 ・Naïve:n = 35, 初回再発:n = 23 ・奏効率 37%;B細胞性 29%, T細胞性 64% ・副作用は食欲不振(45%…
27 followers
1,620 followers
RT @sgvet1209: 犬のリンパ腫の新規治療薬Verdinexor(KPT-335)のPhase Ⅱ試験 ・XPO1を選択的に阻害 ・Naïve:n = 35, 初回再発:n = 23 ・奏効率 37%;B細胞性 29%, T細胞性 64% ・副作用は食欲不振(45%…
925 followers
Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in #dogs with #lymphoma @BMC_series | #ECM https://t.co/PCahfQeH9X
2,814 followers
phase II study of the oral selective inhibitor of nuclear export KPT-335 in dogs with #lymphoma: treatment resulted in an objective response rate of 71%, in dogs with T-cell lymphoma & was well tolerated (grade 1–2 anorexia the most common adverse ev